These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
429 related items for PubMed ID: 19661251
21. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis]. Kang WL, Xie YG, Tan WG, Chu NH, Li L, You YH, Yang YZ, Wang XM, Yan XL, Miao ZP, Duanmu HJ. Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883 [Abstract] [Full Text] [Related]
22. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. Sangaré L, Diandé S, Badoum G, Dingtoumda B, Traoré AS. Int J Tuberc Lung Dis; 2010 Nov; 14(11):1424-9. PubMed ID: 20937182 [Abstract] [Full Text] [Related]
23. New drugs for tuberculosis. Grassi C, Peona V. Eur Respir J Suppl; 1995 Sep; 20():714s-718s. PubMed ID: 8590571 [Abstract] [Full Text] [Related]
29. Recurrence after successful treatment among patients with multidrug-resistant tuberculosis. Lee J, Lim HJ, Cho YJ, Park YS, Lee SM, Yang SC, Yoo CG, Kim YW, Han SK, Yim JJ. Int J Tuberc Lung Dis; 2011 Oct; 15(10):1331-3. PubMed ID: 22283890 [Abstract] [Full Text] [Related]
31. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T. Clin Infect Dis; 2009 May 15; 48(10):1354-60. PubMed ID: 19348594 [Abstract] [Full Text] [Related]
32. [The rate and pattern of drug resistance in Mycobacterium tuberculosis at various sites of the disease]. Vishnevskiĭ BI, Steklova LN. Probl Tuberk Bolezn Legk; 2008 May 15; (12):5-8. PubMed ID: 19227317 [Abstract] [Full Text] [Related]
35. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Törün T, Tahaoğlu K, Ozmen I, Sevim T, Ataç G, Kir A, Güngör G, Bölükbaşi Y, Maden E. Int J Tuberc Lung Dis; 2007 Sep 15; 11(9):979-85. PubMed ID: 17705975 [Abstract] [Full Text] [Related]
37. Fluoroquinolones in multidrug-resistant tuberculosis. Mohapatra PR. Am J Respir Crit Care Med; 2004 Oct 15; 170(8):920-1. PubMed ID: 15475406 [No Abstract] [Full Text] [Related]
38. Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China. Qi W, Harries AD, Hinderaker SG. Int J Tuberc Lung Dis; 2011 Jan 15; 15(1):137-9. PubMed ID: 21276311 [Abstract] [Full Text] [Related]
39. [Some epidemiological and clinical aspects of primary resistance to the classic drugs in patients with pulmonary tuberculosis]. Zierski M. Tuberkuloza; 1966 Jan 15; 18(1-3):300-6. PubMed ID: 16296101 [No Abstract] [Full Text] [Related]
40. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis. Lee H, Jeong BH, Park HY, Jeon K, Huh HJ, Lee NY, Koh WJ. Antimicrob Agents Chemother; 2016 Jan 15; 60(1):471-7. PubMed ID: 26525801 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]